Clio Formulations Profile
Key Indicators
- Authorised Capital ₹ 0.90 M
as on 19-12-2024
- Paid Up Capital ₹ 0.90 M
as on 19-12-2024
- Company Age 4 Year, 7 Months
- Last Filing with ROC 31 Mar 2024
- Revenue 114.57%
(FY 2023)
- Profit 153.40%
(FY 2023)
- Ebitda 206.02%
(FY 2023)
- Net Worth 34.29%
(FY 2023)
- Total Assets 8.66%
(FY 2023)
About Clio Formulations
The Company is engaged in the Pharma Industry.
The Company's status is Active, and it has filed its Annual Returns and Financial Statements up until 31 March 2024. It's a company limited by shares with an authorized capital of Rs 0.90 M and a paid-up capital of Rs 0.90 M, as per Ministry of Corporate Affairs (MCA) records.
Sushma Dixit, Sonal, and Sunil Venkateshwar serve as directors at the Company.
- CIN/LLPIN
U93000UP2020PTC129267
- Company No.
129267
- Company Classification
Private Limited Indian Non-Government Company
- Incorporation Date
08 Jun 2020
- Date of AGM
30 Sep 2024
- Date of Balance Sheet
31 Mar 2024
- Listing Status
Unlisted
- ROC Code
Roc Kanpur
Industry
Company Details
- Location
Kanpur Nagar, Uttar Pradesh, India
- Telephone
- Email Address
- Website
-
- Social Media-
Who are the key members and board of directors at Clio Formulations?
Board Members(3)
| Name | Designation | Appointment Date | Status |
|---|---|---|---|
Sushma Dixit  | Director | 09-Jul-2021 | Current |
| Sonal | Director | 10-Dec-2020 | Current |
| Sunil Venkateshwar | Whole-Time Director | 08-Jun-2020 | Current |
Financial Performance of Clio Formulations.
Clio Formulations Private Limited, for the financial year ended 2023, experienced significant growth in revenue, with a 114.57% increase. The company also saw a substantial improvement in profitability, with a 153.4% increase in profit. The company's net worth Soared by an impressive increase of 34.29%.
- Key Matrics
- Balance Sheet
- Profit and Loss
- Cash Flow
- Ratios
| Metric |
| (FY 2022) | (FY 2021) | (FY 2020) | (FY 2019) | ||
|---|---|---|---|---|---|---|---|
| Total Revenue |
| ||||||
| Revenue from Operations |
| ||||||
| Total Assets |
| ||||||
| Profit or Loss |
| ||||||
| Net Worth |
| ||||||
| EBITDA |
|
What is the Ownership and Shareholding Structure of Clio Formulations?
Unlock access to Clio Formulations's control and ownership data, Corporate Shareholding Patterns, Funding (security allotment) details, Foreign Institutional Investor information, Directors and Key Management Personnel (KMP) Remuneration, Group Structure, Overseas Direct Investment and other pertinent data.
Related Corporates (Common Directorship)
Kabir Hospital Private LimitedActive 21 years 10 monthsSushma Dixit and Sunil Venkateshwar are mutual person
Charges (Loans)
There are no open charges registered against the company as per our records.
How Many Employees Work at Clio Formulations?
Clio Formulations has a workforce of 0 employees as of Apr 03, 2024. Unlock access to detailed historical data on individuals associated with the company, including employment records, contributions to the Employees' Provident Fund Organization (EPFO), and other related insights.
Deals i
Gain comprehensive insights into the Deals and Valuation data of Clio Formulations, offering detailed information on various transactions, including security allotment data. Explore the intricate details of financial agreements, mergers, acquisitions, divestitures, and strategic partnerships that have shaped Clio Formulations's trajectory.
Rating
Access the credit rating data, providing valuable insights into the company's creditworthiness and financial stability. Explore assessments from leading credit rating agencies, evaluating factors such as debt obligations, liquidity, profitability, and overall financial health.
Alerts
Stay informed about regulatory alerts and litigation involving and associated companies. Receive timely updates on legal proceedings, regulatory changes, and compliance issues that may impact the company's operations, reputation, and financial performance. Monitor litigation involving subsidiaries, joint ventures, and other affiliated entities to assess potential risks and liabilities.
